WaveMan
WaveMan · Company
NSPR · Inspiremd, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NSPR InspireMD (NSPR) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001433607
Quote by TradingView
Cluster · 4 insidersC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
18
13F, latest reported quarter

What the filings say about NSPR

Insiders, 180 days
+$343.0K net bought
4 buyers · 1 seller · 0% of sales under a 10b5-1 plan

InspireMD insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, InspireMD, Inc. insiders bought a net $343.0K of stock across 61 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Stuka Paul
Director
BUY
2026-05-29 SECtraded 2026-05-27
20,000
$17.6K
-54.5%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on May 14, 2026.
  • -27.0% median (-17.3% mean) 90-day return after 19 previous buys.
  • The trade is 3.0% of the 667,871 shares held after it.
  • 3 other insiders bought within 30 days.
  • 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stuka Paul bought about $17.6K of NSPR on May 27, 2026; 3 other insiders bought within 30 days and 18 funds added in the latest 13F quarter.
Gleason Shane Thomas
Chief Commercial Officer
SELL
2026-05-21 SECtraded 2026-05-19
22,778
$23.0K
-55.0%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Feb 2, 2026.
  • The trade is 2.2% of the 1,053,882 shares held after it.
  • No other insider sold within 30 days.
  • 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Gleason Shane Thomas sold about $23.0K of NSPR on May 19, 2026; 18 funds added in the latest 13F quarter.
Stuka Paul
Director
BUY
2026-05-15 SECtraded 2026-05-14
5,000
$5.8K
-57.1%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on May 13, 2026.
  • -27.2% median (-16.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.8% of the 647,871 shares held after it.
  • 3 other insiders bought within 30 days.
  • 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stuka Paul bought about $5.8K of NSPR on May 14, 2026; 3 other insiders bought within 30 days and 18 funds added in the latest 13F quarter.
Stuka Paul
Director
BUY
2026-05-15 SECtraded 2026-05-13
10,000
$11.6K
-57.1%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 buys), the last on May 11, 2026.
  • -27.0% median (-16.3% mean) 90-day return after 17 previous buys.
  • The trade is 1.6% of the 642,871 shares held after it.
  • 3 other insiders bought within 30 days.
  • 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stuka Paul bought about $11.6K of NSPR on May 13, 2026; 3 other insiders bought within 30 days and 18 funds added in the latest 13F quarter.
Slosman Marvin
CEO and President
BUY
2026-05-13 SECtraded 2026-05-12
21,000
$25.2K
-60.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 30, 2025.
  • The trade is 0.6% of the 3,556,658 shares held after it.
  • 3 other insiders bought within 30 days.
  • 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Slosman Marvin bought about $25.2K of NSPR on May 12, 2026; 3 other insiders bought within 30 days and 18 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$343.0K over 180 days
more than 84% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
18 funds bought in last quarter
below 75% of Medical Devices
Revenue
+28.1% year over year
more than 78% of Medical Devices
Margin
-543.3% net margin
below 93% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 89% of Medical Devices
The situation: each line is one rule over one dataset
4 insiders independently bought a net $343.0K while the stock fell 64% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 11 in the prior 90
Why it matters
The absence is the signal: 11 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch NSPR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-80.0%12M
-80%-53%-26%+2%2025-102025-122026-022026-042026-062026-082026-10 2026-05-07 · ROUBIN GARY S bought $106.2K2026-05-07 · Ward Scott R. bought $84.2K2026-05-08 · Stuka Paul bought $76.1K2026-01-21 · Gleason Shane Thomas sold $28.5K2026-05-12 · Slosman Marvin bought $25.2K2026-05-19 · Gleason Shane Thomas sold $23.0K2025-11-12 · Stuka Paul bought $21.8K2026-01-28 · Gleason Shane Thomas sold $20.5K2025-12-04 · Stuka Paul bought $18.7K2026-05-06 · Ward Scott R. bought $18.4K2026-05-27 · Stuka Paul bought $17.6K2026-01-22 · Gleason Shane Thomas sold $13.2K2026-05-11 · Stuka Paul bought $11.9K2026-05-13 · Stuka Paul bought $11.6K2025-12-05 · Stuka Paul bought $9.4K2025-12-09 · Stuka Paul bought $9.2K2026-01-29 · Gleason Shane Thomas sold $8.2K2026-01-27 · Gleason Shane Thomas sold $7.9K2026-05-07 · Stuka Paul bought $7.3K2026-05-14 · Stuka Paul bought $5.8K2025-12-09 · Stuka Paul bought $4.9K2026-01-30 · Gleason Shane Thomas sold $4.7K2026-01-20 · Gleason Shane Thomas sold $4.7K2026-02-02 · Gleason Shane Thomas sold $4.7K2026-01-15 · Gleason Shane Thomas sold $4.6K2026-01-16 · Gleason Shane Thomas sold $3.6K2026-02-02 · Gleason Shane Thomas sold $3.2K2026-05-06 · Stuka Paul bought $1.7K2026-04-24 · Marvin Slosman filed a 5%+ stake (5.18%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NSPR: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
6,752,968 sh
$4.7M
Rosalind Advisors, Inc.
3,905,743 sh
$2.7M
Aberdeen Group plc
3,698,364 sh
$2.6M
ORBIMED ADVISORS LLC
3,133,405 sh
$2.2M
Parkman Healthcare Partners LLC
2,416,518 sh
$1.7M

Congress trades in NSPR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Marvin Slosman
Activist 13D · 2026-04-24
5.18%

NSPR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NSPR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$80.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.7K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$16.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Marvin Slosman
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.1M
$1.3M
$1.8M
+107%
n/a
2024
$3.3M
$2.4M
$1.6M
+206%
n/a
2023
$3.2M
$5.9M
$1.5M
+227%
n/a
2022
$696.8K
$115.3K
$492.3K
-83%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $343.0K bought by insiders over 180 days, 18 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

NSPR financials

Revenue growth
+28.1%
XBRL, annual
Net margin
-543.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-484.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$42.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-202.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-134.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-180.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-203.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$9.0M$7.0M$6.2M$5.2M
Gross profit$2.6M$1.5M$1.8M$1.1M
Operating income-$49.6M-$33.5M-$21.1M-$18.7M
Net income-$48.8M-$32.0M-$19.9M-$18.5M
EPS (diluted)-0.76-0.76-0.82-2.35
Operating cash flow-$35.1M-$21.9M-$16.4M-$15.5M
Cash$8.9M$18.9M$9.6M$4.6M
SEC XBRL, fiscal years, as known on 2026-10-28

NSPR Stock Sonar score 5/7 axes

Find similar shapesCompare

NSPR ranks highest on insider conviction (87th percentile) and growth (78th), and lowest on profitability (12th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
12
Inputs
  • Return on equity-202.8% · 14 pct, sector of 183
  • Return on assets-134.6% · 12 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-180.7% · 10 pct, sector of 188
Growth
78
Inputs
  • Revenue growth, YoY+28.1% · 78 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
87
Inputs
  • Net Form 4 buying (codes P and S), 180d$343K · 83 pct, sector of 140
  • Insider buyers, 180d4 · 91 pct, sector of 142
Institutional and government
25
Inputs
  • Funds adding, latest quarter18 · 25 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
47
Inputs
  • Short interest, % of float+0.1% · 91 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+35.2% · 4 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NSPR filings, in plain words

Are InspireMD insiders buying or selling NSPR?

In the 180 days to 2026-10-28, InspireMD insiders were net buyers, a net $343.0K: $366.0K of purchases and $23.0K of sales reported on Form 4, by 4 buyers and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, InspireMD insiders were net buyers of NSPR, a net $343.0K across purchases and sales reported on Form 4 by 4 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 4 insiders reported purchases in that window. The latest 5% ownership filing is a 13D by Marvin Slosman, filed 2026-04-24, for 5.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies